Press Release – New York, NY – January 11, 2016 – Sichenzia Ross Friedman Ference LLP partners Gregory Sichenzia, Thomas Rose, Henry Nisser and Tara Guarneri-Ferrara and counsel Peter DiChiara joined representatives of client Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, at the NASDAQ MarketSite in Times Square to ring the January 11 opening bell.
They took the stage along with a group of Oasmia Pharmaceutical AB’s leaders, including Executive Chairman Julian Aleksov.
Oasmia Pharmaceutical AB’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company is listed on Nasdaq Stockholm (OASM.ST), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and The Nasdaq Capital Market (OASM.US).
Photographs of the occasion can be viewed by clicking here.
[starbox id=1]
